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ORIGINAL RESEARCH ARTICLE
BACKGROUND: Extracellular matrix (ECM) remodeling contributes to in-
stent restenosis and thrombosis. Despite its important clinical implications, 
little is known about ECM changes post–stent implantation.
METHODS: Bare-metal and drug-eluting stents were implanted in pig 
coronary arteries with an overstretch under optical coherence tomography 
guidance. Stented segments were harvested 1, 3, 7, 14, and 28 days 
post-stenting for proteomics analysis of the media and neointima.
RESULTS: A total of 151 ECM and ECM-associated proteins were identified 
by mass spectrometry. After stent implantation, proteins involved in regulating 
calcification were upregulated in the neointima of drug-eluting stents. The 
earliest changes in the media were proteins involved in inflammation and 
thrombosis, followed by changes in regulatory ECM proteins. By day 28, 
basement membrane proteins were reduced in drug-eluting stents in 
comparison with bare-metal stents. In contrast, the large aggregating 
proteoglycan aggrecan was increased. Aggrecanases of the ADAMTS (a 
disintegrin and metalloproteinase with thrombospondin motifs) family 
contribute to the catabolism of vascular proteoglycans. An increase in 
ADAMTS-specific aggrecan fragments was accompanied by a notable shift 
from ADAMTS1 and ADAMTS5 to ADAMTS4 gene expression after stent 
implantation. Immunostaining in human stented coronary arteries confirmed 
the presence of aggrecan and aggrecan fragments, in particular, at the contacts 
of the stent struts with the artery. Further investigation of aggrecan presence in 
the human vasculature revealed that aggrecan and aggrecan cleavage were 
more abundant in human arteries than in human veins. In addition, aggrecan 
synthesis was induced on grafting a vein into the arterial circulation, suggesting 
an important role for aggrecan in vascular plasticity. Finally, lack of ADAMTS-5 
activity in mice resulted in an accumulation of aggrecan and a dilation of the 
thoracic aorta, confirming that aggrecanase activity regulates aggrecan 
abundance in the arterial wall and contributes to vascular remodeling.
CONCLUSIONS: Significant differences were identified by proteomics 
in the ECM of coronary arteries after bare-metal and drug-eluting stent 
implantation, most notably an upregulation of aggrecan, a major ECM 
component of cartilaginous tissues that confers resistance to compression. 
The accumulation of aggrecan coincided with a shift in ADAMTS gene 
expression. This study provides the first evidence implicating aggrecan and 
aggrecanases in the vascular injury response after stenting.
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Percutaneous coronary intervention with stent implantation has become the most widely used treatment for coronary artery disease. Use of 
stents reduced the impact of acute elastic recoil and oc-
clusive dissection on restenosis observed with balloon 
angioplasty.1,2 However, stent implantation induced an 
excessive healing process, which, in the case of bare-
metal stents (BMS), led to neointimal hyperplasia and 
in-stent restenosis. The introduction of drug-eluting 
stents (DES) reduced the burden of in-stent restenosis 
and repeat revascularization.3,4 However, DES implanta-
tion delays vessel reendothelialization because of the 
nonselective nature of these drugs, resulting in an in-
creased risk of late and very late stent thrombosis re-
quiring prolonged dual antiplatelet therapy.5 Late stent 
thrombosis has also been associated with the inflam-
mation and hypersensitivity reactions to the nonbio-
compatible polymer coatings on DES.6 Moreover, in the 
long term, neoatherosclerosis is likely to occur earlier 
in DES than in BMS.7 Second-generation DES with du-
rable biocompatible polymers are the current standard 
of care because of their excellent efficacy and safety. 
A further development in stent technology uses biode-
gradable polymers and fully biodegradable nonmetallic 
scaffolds, as well.8,9
However, despite continuous development in 
technology, in-stent restenosis remains a consider-
able cause of stent failure.10 Neointimal hyperplasia 
involves the interaction between inflammatory cells, 
platelets, smooth muscle cells (SMCs), and endothe-
lial cells (ECs) leading to progressive obliteration of 
the vascular lumen.11 Platelet activation and inflam-
mation as an early response to stent deployment re-
sult in increased SMC migration, proliferation, and 
extracellular matrix (ECM) production. Yet, little is 
known about changes in ECM composition on vascu-
lar stent injury, even though >50% of the neointimal 
hyperplasia consists of ECM proteins.12 Our current 
knowledge of ECM remodeling after stent injury and 
during neointima formation is mainly based on histo-
pathologic analysis investigating the role of only few 
selected ECM proteins.12,13 In comparison, proteomics 
is a powerful underpinning technology to profile not 
just individual ECM proteins by antibody staining, but 
to characterize the different stages of ECM remod-
eling by liquid chromatography tandem mass spec-
trometry (LC-MS/MS).
Therefore, the aim of the present study was to use 
proteomics to characterize ECM remodeling in porcine 
coronary arteries stented with BMS and DES. Pigs are 
well suited for these studies, because the stages of the 
healing process closely resemble the human disease, 
but the time course of neointimal hyperplasia forma-
tion is notably shorter.14,15
METHODS
An expanded Methods is available in the online-only Data 
Supplement. The data, analytic methods, and study materi-
als will not be made available to other researchers for pur-
poses of reproducing the results or replicating the procedure 
because of the limited amount of tissues. The proteomics 
data, however, are deposited in PRIDE16 with the data set 
identifiers PXD005726 and 10.6019/PXD005726.
Porcine Model of Stent Injury
All porcine animal procedures were approved by the local 
ethical committee for animal experiments, Institute of 
Pharmacology Polish Academy of Science, Cracow, Poland. 
Twelve healthy male and female domestic pigs (3–4 months 
old, 28–48 kg) underwent percutaneous coronary interven-
tion through transfemoral access. To prevent the risk of in-
stent thrombosis, pigs received a loading dose of aspirin 
and clopidogrel orally 24 hours before intervention and 
remained on this dual antiplatelet therapy until termination. 
The coronary arteries of each animal (left anterior descend-
ing, left circumflex, and right coronary arteries) were either 
stented with a BMS (MULTI-LINK cobalt-chromium stent, 
Abbott Vascular) or a DES based on the same cobalt-chro-
mium platform (XIENCE PRO everolimus-eluting stent with 
durable fluoropolymer, Abbott Vascular) or had balloon 
angioplasty (BA) alone. Full strut expansion was achieved 
for each deployed stent. Quantitative coronary angiography 
and optical coherence tomography (OCT) were performed 
1, 3, 7, 14, or 28 days post–stent implantation, followed by 
harvesting of the coronary arteries. The neointima lesions 
that had developed in stented arteries at day 28 were dis-
sected from the media and analyzed separately. In total, 31 
samples were analyzed by LC-MS/MS for the media (n=3 
BMS and n=3 DES at each time point 1, 3, 7, and 28 days; 
Clinical Perspective
What Is New?
• Despite continuous development in stent tech-
nology, in-stent restenosis and neoatherosclerosis 
remain a considerable cause of stent failure.
• A proteomics approach to identify extracellular 
matrix protein changes in response to bare-metal 
stent and drug-eluting stent insertion revealed dif-
ferential expression of aggrecan, a proteoglycan 
that is usually associated with articular cartilage.
• Aggrecanase activity is part of the vascular injury 
response post-stenting.
What Are the Clinical Implications?
• Aggrecan cleavage is the hallmark of cartilage 
degeneration in a number of degenerative diseases 
including rheumatoid arthritis and osteoarthritis.
• Aggrecanase activity might offer new drug tar-
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n=4 BA early [day 1 to day 3] and n=3 BA late [day 14 to 
day 28]). For the neointima, a total of 14 samples were ana-
lyzed (n=7 BMS, n=7 DES at 28 days). Six coronary arteries 
of 4.5-month-old healthy pigs were harvested as unstented 
controls.
ECM Extraction
The ECM proteins for the media were extracted in a 3-step 
manner with a method previously developed in our labora-
tory for the enrichment of ECM proteins.17 In brief, newly syn-
thesized, loosely bound ECM proteins were extracted in 0.5 
mol/L NaCl (1.5 hours), followed by decellularization of the 
tissue in 0.08% sodium dodecyl sulfate (1.5 hours) to remove 
intracellular material. Eventually the tissue pieces were incu-
bated in 4 mol/L guanidine HCl buffer (48 hours) by vigorous 
shaking at room temperature to extract the strongly bound 
ECM components. The buffers contained protease inhibitors 
and EDTA to prevent ECM protein degradation by proteases. 
Proteins of the thinner neointimal tissues were extracted only 
in guanidine HCl buffer for 48 hours.
Proteomics Analysis in Porcine Tissue
After deglycosylation, proteins were subjected to in-solution 
digestion and analyzed by LC-MS/MS. Fifteen micrograms of 
deglycosylated proteins of the guanidine HCl extracts were 
denatured with 6 mol/L urea and 2 mol/L thiourea, reduced 
with 10 mmol/L dichlorodiphenyltrichloroethane, and alkyl-
ated with 50 mmol/L iodoacetamide, followed by acetone 
precipitation of the proteins and tryptic digestion overnight. 
Subsequently, peptides were cleaned up using C18 spin plates 
and separated on a nanoflow high-performance LC column 
(Acclaim, ThermoFisher) using an UltiMate 3000 RSLCnano 
LC system (ThermoFisher) interfaced to a Q Exactive Plus 
Orbitrap mass spectrometer (ThermoFisher). MS/MS analysis 
was performed on the 15 most abundant ions in each full 
MS scan with dynamic exclusion enabled.18 Raw files were 
searched using Proteome Discoverer 1.4 against a custom-
made database, containing porcine ECM proteins with a 
human proteome background (UniProtKB/Swiss-Prot Release 
2014_06, 20220 protein entries) using Mascot. All data were 
exported to mzIdentML format using Scaffold and deposited 
to the ProteomeXchange Consortium via the PRIDE partner 
repository.
Immunohistochemistry in Human 
Specimen
Human samples were collected under the Bristol Coronary 
Biobank ethical approval 08/H0107/48. The artery including 
stent was fixed in 10% formalin, then the stent was removed, 
and the tissues were paraffin embedded and sectioned at 
3-µm thickness by using a microtome. For immunostain-
ing, deparaffinized and rehydrated samples were incubated 
in 0.3% H2O2 for 10 minutes to block endogenous peroxi-
dases, then incubated in a boiling water bath in preheated 10 
mmol/L sodium citrate buffer (pH 6.0) for antigen retrieval. 
Sections were blocked with either 20% goat (for rabbit 
primary) or rabbit serum (for goat primary) in phosphate-
buffered saline for 1 hour and subsequently incubated with 
primary antibody or matched rabbit IgG control (5 µg/mL) in 
1% goat or rabbit serum and incubated at 4°C overnight. 
Primary antibodies were used to aggrecan (1:400; Abcam, 
ab36861), the NITEGE neoepitope of aggrecan (1:400; 
Thermo, AF-PA11746), hyaluronan and proteoglycan link 
protein 1 (HPLN1) (1:200; Abcam, ab103455), the DPEAAE 
neoepitope of versican (1:400; Abcam, ab19345), matrix 
Gla protein (MGP) (1:100; Abcam, ab86233), and secreted 
phosphoprotein 24 (SPP24) (1:50; sc-169408, Santa Cruz). 
Biotinylated goat anti-rabbit (1:250; Sigma, B7389) or rab-
bit anti-goat (1:250; Dako, E0466) secondary antibodies were 
applied for 1 hour, followed by wash steps and Extravidin-HRP 
(1:250; Sigma, E2886) incubation. 3,3ʹ-Diaminobenzidine tet-
rahydrochloride solution (Vector) for 10 minutes was used for 
detection. Sections were washed in dH2O, counterstained for 
15 seconds in modified Harris Hematoxylin, dehydrated, and 
mounted in DPX. Histological slides were digitally scanned 
using a digital scanning system (LEICA SCN400F) to provide a 
high-resolution digital image.
Statistical Analysis
Data are shown as average±standard error of the mean. 
MS data were quantified using ion intensities (total ion cur-
rent). IBM SPSS statistics software (version 22) and Microsoft 
Excel (version 15.20) were used for statistical calculations, 
GraphPad Prism (version 6.0e) and Microsoft Excel (version 
15.20) for data illustration. For OCT analysis, 2-way analysis 
of variance was applied to assess neointimal volume, minimal 
lumen area, and strut coverage between BMS and DES at dif-
ferent time points. One-way analysis of variance was applied 
for changes in protein abundance and gene expression in 
BMS and DES at different time points. Unpaired Student t test 
with unequal variance was applied for proteomics differences 
between neointimal BMS and DES, BA early and late, for dif-
ferences between BMS and DES at each time point (visualized 
as a volcano plot for changes at day 28), and the comparison 
between BMS or DES day 28 versus BA late, as well. Unpaired, 
2-tailed Student t test with unequal variance was also used 
for the proteomics data in mice, and comparisons on murine 
aortic diameter, blood pressure, and cardiac output, as well. 
MultiExperiment Viewer software (MeV, version v4.9) was 
applied using Pearson correlation for protein clustering. For 
gene expression analysis of porcine tissue, t tests were applied 
for differences between BMS and DES and regression analy-
sis for changes at different time points (P value for trend). 
Student t test with unequal variance was used for densitom-
etry quantification of immunoblots. Correction for multiple 
comparisons was performed using the Benjamini-Hochberg 
procedure,19 controlling the false discovery rate. Uncorrected 
P values and false discovery rate are presented in the tables. 
P values <0.05 were considered significant. A false discovery 
rate threshold of 10% was applied.
RESULTS
Proteomics Analysis of a Porcine Model 
of Stent Injury
BMS or DES were implanted in porcine coronary arter-
ies. Coronary arteries subjected to BA alone without 
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was performed at 5 time points 1, 3, 7, 14, and 28 
days post–stent implantation (Figure  1B). The OCT 
analysis revealed that, at 14 days post–stent implan-
tation, neointimal volume was higher in BMS than in 
DES (P=0.025) with no significant difference at day 
28. The minimal lumen area and the stent strut cover-
age were not different for BMS and DES during the 
28-day follow-up. Time points without significant dif-
ferences were chosen for proteomic analysis to iden-
tify differences in the ECM composition. In total, 45 
samples were analyzed by proteomics (Figure I in the 
online-only Data Supplement). Characteristics of all 
samples are summarized in Table I in the online-only 
Data Supplement.
A 3-step extraction method as previously described 
was used to sequentially extract the ECM proteins of 
the vascular media.16 Twenty-eight days post–stent 
implantation, a neointima had evolved on top of the 
stent struts regardless of the stent type. The neointi-
ma was separated from the media before proteomics 
analyses. Following deglycosylation and tryptic diges-
tion, proteomics analysis of the neointima and the 
media was performed by LC-MS/MS (Figure 1C). Du-
plicate measurements performed on the neointima 
samples showed good reproducibility for spectral 
counts and sequence coverage, and number of iden-
tified peptides, as well (Figure II in the online-only 
Data Supplement).
To improve the identification of ECM proteins on 
MS, a custom-made pig ECM protein database was 
generated for a database search containing a compre-
hensive porcine sequence list of previously published 
ECM proteins (Figure III in the online-only Data Sup-
plement). A total of 151 unique ECM proteins were 
identified overall in the neointima and the media with 
a minimum of 2 high-confidence peptides (Figure IV 
in the online-only Data Supplement, Tables II through 
IV in the online-only Data Supplement). Proteins only 
identified in the media (n=11) or neointima (n=26) are 
marked with an asterisk.
Comparison of the Neointima of DES and 
BMS
In comparison with BMS, the neointima of arteries with 
DES implantation contained fewer structural constitu-
ents of the ECM like collagen type I, III, V, and regu-
latory ECM proteins, such as biglycan, lumican, fibro-
modulin, or periostin, as well (Figure 2A); in contrast, 
proteins involved in the regulation of calcification such 
as MGP, SPP24, and bone morphogenetic protein 1 
were increased (Figure 2B). It is interesting to note that 
proteomics also uncovered the presence of chondroad-
herin in coronary arteries with DES (Figure  2B). This 
small leucine-rich proteoglycan (SLRP) has not been 
previously detected in the vasculature at the protein 
level. Next, we tested whether everolimus treatment 
had an effect on calcification of human aortic SMCs 
in culture using the o-cresolphthalein assay (Figure 2C). 
Everolimus was coated on the DES used in porcine coro-
nary arteries. Indeed, an inhibition of calcification was 
observed on everolimus treatment. Immunohistochem-
istry localized both MGP and SPP24 in human coronary 
arteries with atherosclerotic plaques with and without 
stent implantation (Figure 2D).
ECM Changes in the Media Post-Stenting
ECM remodeling in response to stent implantation 
was compared at 4 different time points (Figure  3A 
and 3B). Coronary arteries subject to BA without stent 
implantation served as controls (Figure 3C). At an early 
stage, proteins regulating hemostasis (eg, plasmino-
gen, fibrinogen, antithrombin-III) and inflammation 
(eg, pentraxin-related protein PTX3, prophenin and 
tritrpticin precursor) were increased, alongside apoli-
poproteins found on very low density lipoprotein par-
ticles, including apolipoproteins C-III, E, and R.20 Pro-
teins with a late response included large aggregating 
proteoglycans (aggrecan, versican), fibrillar collagens 
(eg, type I, III, and V), SLRPs (decorin, biglycan, fibro-
modulin, podocan, asporin), and matricellular pro-
teins (eg, periostin, tenascin, SPARC [secreted protein 
acidic and rich in cysteine]). In general, fewer proteins 
changed in the BA group than in stented arteries, and 
more pronounced changes were seen in DES than in 
BMS (Figure 3D; Table V in the online-only Data Sup-
plement). Differences in the ECM between DES and 
BMS became most obvious at day 28 (Figure 3E) and 
were not revealed by OCT imaging. Thus, DES not only 
affected cell proliferation, but also the composition of 
the ECM.
Comparison of the Media of DES  
and BMS
At day 28, the antiproliferative effects of DES in com-
parison with BMS were reflected in a lower abundance 
of basement membrane proteins such as CO4A2 (col-
lagen α-2 IV), COIA1 (collagen α-1 XVIII), and LAMB1 
(laminin β-1), LAMB2 (laminin β-2), and LAMC1 (lam-
inin γ-1 ), as well (Figure 4A; Table VI in the online-only 
Data Supplement). In contrast, aggrecan was upregu-
lated after stenting, in particular, in DES (Figure  4B). 
Aggrecan is the major large aggregating proteoglycan 
in the articular cartilage and interacts with hyaluronic 
acid. Its rise mirrored the increase of versican, the ma-
jor large aggregating proteoglycan in the vasculature 
(Figure 4B). Aggregates of aggrecan and versican with 
hyaluronic acid are stabilized by HPLN1. HPLN1 was re-
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Figure 1. Porcine model of stent injury.  
A, Pigs underwent PCI with BMS/DES/BA treatment. Coronary arteries were retrieved for proteomics at 1, 3, 7, 14, and 28 
days after stent deployment. The evolved neointimal lesions at day 28 were analyzed separately. In total, 45 samples were ana-
lyzed by LC-MS/MS. B, Quantitative analysis of the neointima was performed by OCT. The neointimal structure was classified 
into homogeneous with peristrut attenuation/ring, heterogeneous, or layered. At 14 days post–stent implantation, neointimal 
volume was higher in BMS than in DES (*P=0.025) with no significant difference at day 28. P=0.89 (2-way ANOVA). C, ECM 
proteins were obtained using our previously published extraction procedure, followed by LC-MS/MS analysis of the deglyco-
sylated tryptic peptides. BA indicates balloon angioplasty; BMS, bare-metal stent; DES, drug-eluting stent; ECM, extracellular 
matrix; GuHCl, guanidine HCl buffer; LC-MS/MS, liquid chromatography tandem mass spectrometry; OCT, optical coherence 
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Figure 2. ECM remodeling in the neointima.  
A, Heat map of proteins with differential abundance. n=7 per group (t test with unequal variance). B, Proteins involved in the regu-
lation of calcification (SPP24, MGP, BMP1) and chondroadherin were predominantly found in the DES group. *P<0.05. BMP 1 and 
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Stent-Induced Changes in Aggrecan and 
Aggrecanase Expression
Because of its unknown function in the vasculature, 
aggrecan was selected for further validation. For com-
parison, we used versican as a structurally and func-
tionally related large proteoglycan. A rise of aggrecan 
and versican expression after stenting was confirmed 
at the transcript level (Figure 4C). Consistent with the 
proteomics findings, there was no equivalent increase 
in the gene expression of hyaluronan and proteoglycan 
link protein 1 (HAPLN1).
Besides gene expression, protein degradation de-
termines the abundance of ECM proteins in the ves-
sel wall. Aggrecanases are members of the ADAMTS 
(a disintegrin and metalloprotease with thrombos-
pondin motifs) family that can cleave aggrecan and 
other large aggregating proteoglycans like versi-
can. Thus, we used neoepitope antibodies that only 
recognize aggrecan and versican after cleavage by 
members of the ADAMTS family, but not by other 
proteases like matrix metalloproteinases. For ag-
grecan, we probed for the signature cleavage at NI-
TEGE373-ARGTV in the interglobular domain at the N-
terminus, whereas versican fragments were detected 
by the DPEAAE neoepitope (Figure 5A). The rise in 
aggrecan was accompanied by increased detect-
ability of the NITEGE neoepitope in DES (Figure 5B, 
Figure V in the online-only Data Supplement). Af-
ter an initial loss at day 3, a similar increase of the 
ADAMTS-generated DPEAAE containing versican 
fragments was observed (Figure 5B, Figure V in the 
online-only Data Supplement). At day 28, both were 
more pronounced in DES than in BMS (Figure  5C, 
Figure VI in the online-only Data Supplement). These 
findings demonstrate, for the first time, the contri-
bution of aggrecanases to vascular remodeling on 
stent implantation.
Because the neoepitope antibodies do not distin-
guish between the activities of the different aggreca-
nases and may reflect differences in substrate avail-
ability rather than changes in aggrecanolytic activity, 
we investigated the gene expression of the 3 main 
ADAMTS enzymes that cleave large aggregating pro-
teoglycans: ADAMTS-1, ADAMTS-4, and ADAMTS-5. 
After stenting, there was a notable reduction in AD-
AMTS1 and ADAMTS5 gene expression, followed 
by an increase in ADAMTS4 (Figure  5D). ADAMTS1 
showed the highest expression levels in porcine coro-
nary arteries (Figure 5E).
Aggrecan and Aggrecanase Expression in 
Human Vascular Cells
To relate the findings in the porcine model of stent in-
jury to human vascular cells, we investigated the gene 
expression of ADAMTS1, -4, and -5 in endothelial cells 
(ECs) and in SMCs from human coronary arteries (Fig-
ure 5F). Human coronary artery ECs express ADAMTS1 
and ADAMTS4, but neither ADAMTS5, aggrecan, nor 
HAPLN1. In contrast, human coronary artery SMCs ex-
press all aggrecanases, including ADAMTS5, and ag-
grecan, versican, and HAPLN1, as well. Thus, resident 
vascular cells can contribute to the aggrecanase activity 
and aggrecan expression in the arterial wall, with ECs 
expressing aggrecanases but not aggrecan.
Aggrecan in the Human Vasculature
To further validate our findings in human tissue, we 
used immunohistochemistry to localize aggrecan and 
aggrecan cleavage in stented human coronary arter-
ies (Figure  6A). Coronary arteries with atherosclerotic 
plaques but without stents served as a reference control. 
Aggrecan and HPLN1 colocalized in the media of control 
arteries. In stented coronary arteries, staining for the ag-
grecan NITEGE neoepitope was observed predominantly 
below the periluminal cellular layer and at the contacts 
of the stent struts with the coronary artery (Figure 6B, 
Figure VII in the online-only Data Supplement). This was 
also supported by the finding that human coronary ar-
tery ECs express ADAMTS1 and ADAMTS4 (Figure 5F). 
To further investigate aggrecan in the human vascu-
lature, we compared specimens of human saphenous 
veins and human thoracic aorta. Targeted proteomics 
revealed that, similar to versican, aggrecan was more 
abundant in the aorta than in veins (Figure 6C, Table VII 
in the online-only Data Supplement). The SLRP decorin 
served as a control. Likewise, the ADAMTS-specific ag-
grecan NITEGE neoepitope was detectable in the aorta 
(Figure 6D, Figure VIII in the online-only Data Supple-
ment). Aggrecan and ADAMTS-induced aggrecan 
cleavage was seen throughout the media of the human 
aorta as confirmed by immunofluorescence staining 
(Figure 6E).
Aggrecan and Aggrecanases in Mice
ADAMTS-5 is the main aggrecan-degrading enzyme 
in mice.21 To examine the effects of ADAMTS-5 on 
the vasculature, we used proteomics to compare the 
Figure 2 Continued. in the control group, thus a t test was not performed. C, Everolimus treatment reduced SMC calcification as 
revealed by Alizarin Red staining and o-cresolphthalein complexone assay. n=triplicates of 4 independent experiments. ***P<0.001 
(t test with unequal variance). D, MGP and SPP24 in human stented and control coronary arteries. Scale bars=1 mm. BMP1 indicates 
bone morphogenetic protein 1; BMS, bare-metal stent; CA, coronary artery; Ctrl, control; DES, drug-eluting stent; ECM, extracellular 
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ECM of aortas from mice lacking the catalytic domain 
of ADAMTS-521 with aortas from littermate controls 
(Table VIII in the online-only Data Supplement). Loss of 
ADAMTS-5 activity resulted in an accumulation of ag-
grecan (Figure  7A) confirming the importance of ag-
grecanases in regulating the abundance of aggrecan in 
the vessel wall. These structural changes in the aortic 
wall were accompanied by an increase in the diameter 
of the thoracic, but not of the abdominal aorta (Fig-
ure 7B). It is noteworthy that cardiac output as mea-
sured by cardiac MRI and blood pressure were not sig-
nificantly different from wild-type controls (Figures IX 
and X in the online-only Data Supplement). This genetic 
mouse model confirms the importance of aggrecanases 
in regulating the abundance of aggrecan in the vessel 
wall and suggests a link between aggrecanase activity 
and aortic diameter.
The higher abundance of aggrecan in stented por-
cine coronary arteries and human aortas in comparison 
with veins is suggestive of mechanical stretch inducing 
aggrecan expression in the vasculature. To explore this 
potential mechanism, veins were grafted into the ca-
rotid arteries of mice.22 After grafting, mice were fed a 
diet of stable isotope-labeled amino acids for 28 days 
to label newly synthesized proteins (Figure  8A). With 
the use of targeted LC-MS/MS analysis (Table IX in the 
online-only Data Supplemental), the incorporation of 
the stable isotope-labeled amino acids was compared 
between ECM proteins in veins, vein grafts, and arter-
ies. Sixty percent of aggrecan peptides were found to 
be labeled in the murine aorta, demonstrating active 
synthesis of this proteoglycan in the arterial wall. In 
contrast, labeled aggrecan peptides were undetectable 
in veins. The incorporation ratio in vein grafts, how-
ever, was comparable with the aorta. Thus, aggrecan 
synthesis was inducible in veins by exposure to arterial 
blood pressure. Representative histological sections are 
shown in Figure 8B, where aggrecan was markedly el-
evated after grafting. The upregulation coincided with 
cleavage of versican as indicated by staining for the 
ADAMTS-specific DPEAAE neoepitope. Thus, besides 
their established role in cartilage, aggrecan and aggre-
Figure 3. ECM remodeling in the media. 
A through C, Heat maps of ECM proteins with differential abundance at different time points. BMS/DES: n=3 per time point. 
P<0.05 (1-way ANOVA). BA: n=3–4 per group. P<0.05 (t test with unequal variance). D, Number of significant protein 
changes in BA late in comparison with BMS and DES at day 28. E, Number of proteins with differential abundance between 
DES versus BMS at day 1, 3, 7, and 28 post–stent implantation. AE indicates adipocyte enhancer; BA, balloon angioplasty; 
BMS, bare-metal stent; DES, drug-eluting stent; ECM, extracellular matrix; IGF, insulin-like growth factor; ITI heavy chain H2, 
interalpha-trypsin inhibitor heavy chain H2; LTBP2, latent-transforming growth factor β-binding protein 2; PTX3, pentraxin-
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Figure 4. ECM composition in DES and BMS in the media.  
A, Volcano plot of differentially expressed proteins between DES and BMS at day 28. n=3 per group (t test with unequal variance). 
B, Changes in aggrecan, versican, and HPLN1 protein abundance at day 1, 3, 7, and 28 post–stent implantation. n=3 per group. 
*P<0.05 (t test with unequal variance). C, Corresponding gene expression in stented (n=3 per time point) and control unstented cor-
onary arteries (n=6). Gene expression values were normalized to unstented control arteries. Linear regression analysis for P value for 
trend. BMS indicates bare-metal stent; DES, drug-eluting stent; ECM, extracellular matrix; HAPLN1, gene name for hyaluronan and 
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Figure 5. Aggrecanase expression in the porcine model of stent injury and comparison to human vascular cells. 
A, The aggrecan neoepitope NITEGE and the versican neoepitope DPEAAE are generated by ADAMTS cleavage. B, Aggrecan 
NITEGE and versican DPEAAE neoepitopes in DES at day 1, 3, 7, and 28 post–stent implantation. n=3 per time point. C, Dif-
ferences between BMS and DES at day 28. n=4 per group. D, Gene expression of ADAMTS1, -4, and -5 in porcine tissue. n=3 
per time point for BMS/DES; n=6 for control coronary arteries. Gene expression values were normalized to unstented control 
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canases are important contributors to ECM remodeling 
in the vasculature on stenting and mechanical stretch 
(Figure 8C).
DISCUSSION
This is the first proteomics analysis to profile the ECM 
remodeling of stented coronary arteries and to com-
pare the effects of DES versus BMS on the vascular 
ECM. Diverging from the traditional focus on collagens 
and matrix metalloproteinases, this study highlights the 
contribution of aggrecan and aggrecanases to ECM re-
modeling after stent implantation. Findings in the large-
animal model were validated in human specimens and 
followed-up in 2 small animal models. Thus far, little is 
known about the role of aggrecan in the vasculature 
and the stimuli that induce its expression.23 We demon-
strate that aggrecan is more abundant in arteries than 
in veins, that the synthesis of aggrecan is inducible by 
grafting veins to arteries, and that aggrecan abundance 
is influenced by aggrecanase activity in the arterial wall.
ECM Changes in the Neointima
The vascular ECM plays a critical role in providing struc-
tural support to the vessel wall and influences cell be-
havior and signaling. Our proteomics comparison of the 
neointima revealed the following findings: First, a more 
organized and structured ECM assembly in the neo-
intima forming over BMS in comparison with DES. Pre-
sumably, ECM organization occurs at an earlier stage 
in arteries treated with BMS than in DES. Second, an 
upregulation of proteins associated with the regulation 
of calcification in neointimal lesions of arteries treated 
with DES. The upregulation of these proteins may be a 
protective response as demonstrated by the presence 
of MGP and SPP24 in human control arteries. MGP is 
thought to act as an inhibitor of calcification.24 Simi-
larly, SPP24 is not osteogenic but binds to and affects 
the activity of bone morphogenetic protein 2.25 Indeed, 
calcification assays in human arterial SCMs demon-
strated an inhibition of calcification under everolimus 
treatment. Everolimus is an inhibitor of the mechanistic 
target of rapamycin (mTOR). Further studies will need 
to clarify whether this observation is directly related 
to the observed ECM protein changes on drug treat-
ment or other drug effects. Drug effects could induce 
a phenotypic change of SMCs. This may also explain 
why MGP and SPP24 appear increased in normal ves-
sels versus stented human vessels. Finally, we observed 
chondroadherin in DES-stented arteries. This SLRP is 
mainly expressed in cartilaginous tissue26 and has been 
previously associated with disc degeneration,27 but its 
expression in the vasculature has never been reported 
at the protein level. Yet, there is evidence for an as-
sociation of chondroadherin with vascular pathology, 
because its transcription was found to be specifically in-
duced in atherosclerotic plaques of femoral arteries.28 It 
remains to be elucidated if these proteins might provide 
a link to the increased incidence or accelerated course 
of de novo atherosclerosis within DES-stented vessels.29
Early Changes on Vascular Injury
Our discovery-based proteomics comparison allowed 
an analysis of ECM proteins during early and late stages 
of vascular healing in response to stents. The early re-
sponse to injury was independent of the applied stent 
type. Some changes were also observed after BA alone 
without stent insertion, indicating a response to vascu-
lar injury rather than stenting. Three different functional 
classes were increased: first, proteins involved in throm-
bosis such as fibrinogen, plasminogen, antithrombin III, 
and thrombospondin, which is in line with findings in 
histopathologic studies of platelet activation and throm-
bosis formation during the early stage of vascular heal-
ing30; second, inflammatory proteins associated with 
innate immunity, such as PTX3 and prophenin and tritrp-
ticin, implicating the recruitment of inflammatory cells to 
the site of vascular injury. Lactadherin, for example, con-
tributes to phagocytic removal of apoptotic cells31 and 
shows a peak expression at 7 days post–stent insertion 
in the DES group. Finally, various apolipoproteins, such 
as apolipoproteins E, C-III, and R and also lipoprotein li-
pase were retained. It is noteworthy that these are very 
low density lipoprotein–associated apolipoproteins.20 We 
have recently observed that plasma levels of very low 
density lipoprotein–associated apolipoproteins predict 
cardiovascular events32 and that these apolipoproteins 
are also present in human atherosclerotic plaques.33
ECM Changes in the Media
ECM changes were observed predominantly after 28 
days, which is likely explained by the time it takes for 
SMCs to lay down enough new ECM. A significant in-
crease at day 28 was seen in fibrillar collagens, such as 
type I, III, and V, and matricellular proteins (periostin, 
Figure 5 Continued. arteries. Cycle threshold (CT) values by qPCR are given as 40-CT (higher values indicate higher expres-
sion). n=6 per group. F, Gene expression of ADAMTS1, -4, and -5 as well as versican, aggrecan, and HAPLN1 in ECs and SMCs 
of human coronary arteries. CT values by qPCR are given as 40-CT (higher values indicate higher expression). HCAEC indicate 
human coronary artery endothelial cell; HCASMC, human coronary artery SMCs; n=triplicates of 3 independent cell passages. 
***P<0.001 (t test with unequal variance). BMS indicates bare-metal stent; DES, drug-eluting stent; EC, endothelial cell; qPCR, 
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Figure 6. Aggrecan in the human vasculature.  
A, Localization of aggrecan, the aggrecan NITEGE, and versican DPEAAE neoepitopes (neo), and HPLN1 in stented and control 
human coronary arteries with the presence of atherosclerosis (*). Arrows mark the contacts of the stent struts with coronary 
artery. Scale bars=1 mm. B, Colocalization of aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE neoepitope 
(Alexa 568, displayed in red) in human stented coronary arteries by immunofluorescence. Note the presence of aggrecan frag-
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tenascin, SPARC) and SLRPs like decorin, biglycan, fi-
bromodulin, podocan, and asporin, as well. These are 
important regulatory proteins and involved in a variety 
of cellular functions such as collagen fibril assembly, 
inflammation, cell proliferation, adhesion, and migra-
tion, and fibrosis, as well.34 In general, more proteins 
showed a significant change in the DES group than 
in the BMS group, with the differences being more 
pronounced at later stages. In DES, a uniform down-
regulation of basement membrane proteins, indica-
tive of the reduced cellularity, was accompanied by an 
increase in aggrecan, also known as cartilage-specific 
proteoglycan core protein.
Aggrecan in the Vasculature
Aggrecan is well studied in cartilage, but its expression 
and function in the vasculature has only recently begun 
to be appreciated. It is the major proteoglycan in carti-
lage35,36 and characterized by its ability to bind hyaluro-
nan, a large carbohydrate polymer, to form even larger 
aggregates.37 Between its G2 and G3 domain aggrecan 
carries numerous glycosaminoglycans, namely keratan 
sulfate and chondroitin sulfate chains, giving the pro-
tein an enormous amount of fixed negative charges 
(Figure 5A). These highly negatively charged glycosami-
noglycans provide the basis for the viscoelastic proper-
ties of cartilage.
Because of its water-attracting property that confers 
resistance to compression, aggrecan may be part of an 
adaptive response of the vasculature to absorb mechan-
ical forces. In addition, proteoglycans present growth 
factors and cytokines to the surrounding tissue,38 and 
their interactions with other ECM components modu-
late a wide range of cellular responses, including inflam-
mation.39 It has been suggested that the lipoprotein 
binding to negatively charged glycosaminoglycan side 
chains might contribute to atherosclerosis.23,40 Aggre-
can expression was demonstrated in advanced lesions 
of atherosclerotic aortas of ApoE/LDLr-deficient mice 
by immunohistochemistry, further supporting that car-
tilage-associated ECM proteins may be involved in the 
pathogenesis of atherosclerosis.41 Similarly, we observed 
staining for aggrecan in the atherosclerotic lesion of the 
human control coronary artery (Figure  6A, *indicates 
plaque location). It is noteworthy that a previous pro-
teomics analysis discovered aggrecan in vascular intimal 
hyperplasia.42 Our proteomics study provides the first 
evidence for an upregulation of aggrecan after stenting 
and on grafting veins from a low- to a high-pressure 
environment. Future studies are needed to investigate 
whether aggrecan or its cleavage products may con-
tribute to the more frequent and accelerated onset of 
neoatherosclerosis in DES.43 Kumar et al44 have recently 
reported that reduced aggrecan cleavage was associ-
ated with decreased macrophage numbers and less ath-
erosclerosis in Adamts4–/– ApoE–/– mice.
Aggrecanases in the Vasculature
Besides aggrecan, the aggrecan NITEGE neoepitope 
was detected in porcine coronary arteries on stent-
ing. This aggrecan neoepitope is generated on diges-
tion by aggrecanases of the ADAMTS family, but not 
by other proteases. Because aggrecan is not abundant 
in uninjured vessels (Figure 4B), the NITEGE neoepitope 
predominantly reflects differences in substrate availabil-
ity (Figure  5B). Instead, the versican DPEAAE neoepi-
tope reflects the loss of aggrecanolytic activity at day 
3 post-stenting (Figure 5B). The neoepitope antibodies 
do not distinguish between the cleavage products of 
ADAMTS-1, ADAMTS-4, and ADAMTS-5 activity. AD-
AMTS1, ADAMTS4, and ADAMTS5, however, showed 
a notable shift in gene expression in stented porcine 
coronary arteries. Expression of ADAMTS1 and AD-
AMTS5 was markedly reduced on stent implantation. 
Instead, ADAMTS4 was induced, in particular, in BMS. 
Human coronary artery ECs only express ADAMTS1 and 
ADAMTS4, whereas human coronary artery SMCs ex-
press ADAMTS1, ADAMTS4, and ADAMTS5, and ag-
grecan, as well. Thus, the loss of arterial ECs on stent-
ing could contribute to the initial loss of aggrecanase 
expression in the vessel wall.45 Moreover, the effects of 
DES might facilitate the accumulation of large aggre-
gating proteoglycans in the vessel wall. Treatment of 
human coronary artery SMCs with everolimus reduced 
gene expression of ADAMTS4, whereas the expression 
levels of ADAMTS1 remained unchanged (data not 
shown). On vascular injury, however, inflammatory cells 
are likely to contribute to the ADAMTS-4 activity in the 
vessel wall.44
Aggrecan and its ADAMTS-cleaved fragments were 
also colocalized in the media of the human thoracic 
aorta. Aggrecanase activity regulates the abundance of 
Figure 6 Continued. image 20×, scale bar=500 µm; Zoomed-in areas 60×, scale bar=25 µm. C, Adjusted peak area for 
aggrecan, versican, and decorin in the human thoracic aorta and saphenous veins as determined by targeted proteomics. 
n=7 per group. *P<0.05, **P<0.01 (t test with unequal variance). D, Immunoblots for the aggrecan NITEGE neoepitope and 
versican in the human thoracic aorta and saphenous veins. The SLRP decorin served as a loading control. n=4 per group. E, 
Colocalization of aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE neoepitope (Alexa 568, displayed in red) in 
human aorta visualized by immunofluorescence. Elastin fibers in white (autofluoresence with 488-nm laser excitation captured 
in the green emission channel). Control sections stained with isotope IgGs. Magnification 60×, scale bars=20 µm. CA indicates 
coronary artery; DAPI, 4ʹ,6-diamidino-2-phenylindole; HPLN1, hyaluronan and proteoglycan link protein 1; IgG, immunoglobu-
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Figure 7. Aggrecan and aggrecanases in the murine aorta. 
A, Volcano plot of differentially expressed proteins between the aorta of wild-type littermate controls (WT) and mice lacking 
the catalytic domain of ADAMTS-5 (Adamts5 Δcat). n=6 (WT), n=5 (Adamts5 Δcat), t test with unequal variance. PGCA indi-
cates aggrecan; MIME, mimecan; and VTNC, vitronectin. B, Aortic diameters of aortic ring (AoR), ascending aorta (AsAo), and 
abdominal aorta (AbAo) as measured by ultrasonography. Representative ultrasound images are shown, values are represented 
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Figure 8. Aggrecan in vascular remodeling.  
A, The isogenic venae cavae were grafted to carotid arteries of mice fed a diet with stable isotope-labeled amino acids. Incor-
poration ratios for aggrecan, versican, and decorin in interposition grafts, vena cava inferior, and aortas. n=8 to 9 per group. 
N.D. indicates not detectable. B, Immunostaining for aggrecan, the versican DPEAAE neoepitope, and decorin. Magnification 
10×, scale bars=200 µm. C, Summary. Changes in ADAMTS expression accompany the increase of the large aggregating pro-
teoglycans aggrecan and versican post-stenting. EC indicates endothelial cell; SILAC, stable isotope labeling with amino acids 
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aggrecan in the vessel wall as evidenced by the buildup 
of aggrecan in the aorta of mice lacking the catalytic do-
main of ADAMTS-5. Their vascular phenotype closely re-
sembled recent observations in Adamts-1 heterozygous 
mice.46 In Adamts-1+/– mice, thoracic aortic aneurysm 
formation and dissection were induced by an increase 
in inducible nitric oxide synthase and medial degenera-
tion. In our analysis, loss of ADAMTS-5 activity resulted 
in thoracic aortic dilation with a buildup of aggrecan. 
This finding extends our previous report on the catabolic 
properties of ADAMTS-5 on vascular proteoglycans and 
its ability to alter proteoglycan-mediated lipoprotein re-
tention in a mouse model of atherosclerosis.23
Strengths and Limitations
A particular strength of our study is the combination of 
proteomics with a clinically relevant large-animal model 
of human disease.15 In the porcine model, peak neointi-
ma growth is observed at 28 days after stent deployment 
corresponding to 6 months in humans. Few changes oc-
cur beyond this time point, with the exception of slight 
neointima thinning later on.14 The pigs, however, are 
young and free of atherosclerosis. A caveat of working 
with porcine tissue is the limited availability of antibod-
ies, and proteomics was key for a comprehensive protein 
analysis without constraints imposed by antibodies.
CONCLUSIONS
The effects of DES go beyond inhibition of SMC prolif-
eration, but have a wider impact on vascular remodel-
ing by altering the composition of the ECM. The antip-
roliferative effect of DES was evident by a reduction in 
basement membrane proteins. Moreover, the decreased 
cellularity was accompanied by increased production 
of large aggregating proteoglycans like aggrecan and 
versican. Aggrecan and aggrecanases are integral com-
ponents during ECM remodeling after stenting. A sum-
mary of our findings is provided in Figure 8C.
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